Research Article

HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib

Qian Jin, Jisheng Zheng, Ming Chen, Na Jiang, Xianrong Xu, and Feihua Huang

Department of Respiratory Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China

Correspondence should be addressed to Qian Jin; jinqian0504@hotmail.com and Feihua Huang; 042111364@fudan.edu.cn

Received 17 October 2020; Revised 30 January 2021; Accepted 14 February 2021; Published 3 March 2021

Copyright © 2021 Qian Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Acquired resistance occurred in the majority of nonsmall cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) therapy, and this may be related to the activation of the HIF-1 pathway. Therefore, we examined the influence of the hypoxia-inducible factor-1 (HIF-1) pathway inhibition on the sensitivity of HCC827 gefitinib-resistant (HCC827 GR) cells with MET amplification to gefitinib.

Methods. We established HCC827 GR cell line with MET amplification and set four groups with different treatment. An MTT assay, a colony formation analysis, and a wound healing assay were performed to determine the sensitivity change of HCC827 GR cells after different treatments. HIF-1α, p-EGFR, and p-Met levels were detected with western blot. Correlations among HIF-1α, p-EGFR, and p-Met levels of HCC827 GR cells with different treatments were analyzed with Pearson’s correlation analysis.

Results. HIF-1 inhibitor YC-1 enhanced the sensitivity of HCC827 GR cells to gefitinib. p-Met level was correlated with HIF-1α level, while there was no correlation between p-Met level and p-EGFR level.

Conclusion. HIF-1 inhibitor YC-1 is able to reverse the acquired resistance of HCC827 GR to gefitinib, and the regulation of the HIF-1 pathway on MET may be one of the mechanisms.

1. Introduction

The acquired resistance of anticancer drugs is a major cause for therapeutic failure in nonsmall cell lung cancer (NSCLC) leading to tumor recurrence, progression, and poor prognosis [1]. For NSCLC patients with EGFR sensitive mutation, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been used clinically as the first-line treatment [2–4]. However, tumor progression inevitably occurred in the majority of NSCLC patients receiving EGFR-TKIs therapy despite the initial obvious and rapid effects of EGFR-TKIs [5]. Many mechanisms such as T790M mutation, human EGFR-2 amplification, and MET amplification may lead to acquired resistance of EGFR-TKIs [6, 7], but there must be many other mechanisms that need further researches.

Hypoxia is a remarkable characteristic of lung cancer [8]. Tumors in hypoxia condition are easier to have gene mutation, more resistant to antitumor therapy, more invasive, and more antiapoptotic [9]. Under hypoxia condition, the hypoxia-inducible factor 1 (HIF-1) signaling pathway is activated and plays an important role on the biological effects of hypoxia [8]. HIF-1 consists of a functional α subunit and a β subunit [10]. In a previous study, the quantity of NSCLC stem cells which were resistant to EGFR-TKIs in EGFR mutant NSCLC was increased under hypoxia condition, and the HIF-1α level was elevated in acquired EGFR-TKI-resistant NSCLC cells [11, 12]. Therefore, we aim at the HIF-1 pathway as a potential target to affect the sensitivity of NSCLC cells to EGFR-TKIs.

In our previous published research, we used HIF-1 inhibitor and activator to regulate the activity of the HIF-1 pathway and found that HIF-1 inhibitor can enhance the sensitivity of HCC827 cells (EGFR-TKIs sensitive EGFR exon 19 mutant NSCLC cell line) to EGFR-TKIs [13]. In order to learn the effect of the HIF-1 pathway on EGFR-TKI acquired resistant NSCLC, we design the present research.

3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1) is a kind of benzyl indazole by chemically synthesizing [14]. It had been found as a HIF-1 inhibitor without cytotoxicity [15]. For the present study, YC-1 and gefitinib were selected...
as HIF-1 inhibitor and EGFR-TKI, respectively. HCC827 gefitinib-resistant (HCC827 GR) cell line was selected as the acquired EGFR-TKI resistant NSCLC cell line. HCC827 GR is generated by exposing HCC827 cells to increasing concentrations of gefitinib, and MET amplification is the mechanism of its acquired resistance [7, 16, 17]. In EGFR-TKI-sensitive NSCLC cells, EGFR was able to regulate MET level through the HIF-1 pathway [18]. In acquired EGFR-TKI-resistance NSCLC cells with MET amplification, EGFR lost its regulation on MET, and whether the HIF-1 pathway remained the regulation on MET kept unclear [7]. In order to make clear the correlation between HIF-1 and MET, acquired gefitinib-resistant HCC827 GR cells with MET amplification was considered to be the ideal cell line for the present study.

Here, we researched whether HIF-1 inhibiting can reverse the acquired gefitinib resistance of HCC827 GR and detected the levels of p-EGFR, HIF-1α, and p-Met to explore whether the relative mechanism was associated with the regulation of HIF-1 on MET.

2. Materials and Methods

2.1. Reagents. Reagents and suppliers were as follows: Droplet Digital PCR QX200 system (Bio-Rad Laboratories Inc., Hercules, CA, USA); antibodies against phosphorylated
hepatocyte growth factor receptor (p-Met), c-Met, phosphorylated EGFR (p-EGFR), and EGFR protein (Abcam, Cambridge, MA, USA); and QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Other reagents and suppliers had been described in our previous research of Jin et al. 2019 [13].

2.2. Establishment of HCC827 GR Cell Line. Human commercially available HCC827 cell line was bought from China Academy of Cell Resource Center, Shanghai Institutes for Biological Sciences as the parental cell. Cell viability of HCC827 in different gefitinib concentrations was measured by MTT assay. HCC827 was continuously exposed to gefitinib beginning at 0.001 μM (equivalent to IC20 in parental HCC827) and increased in a stepwise manner to 1 μM to generate a resistant cell line. The gefitinib concentrations was increased stepwise to 0.006 μM, 0.05 μM, 0.1 μM, 0.5 μM, and 1 μM, equivalent to IC30, IC40, IC50, IC60, and IC70 in parental cells, respectively, until these cells recovered near-normal growth kinetics. The total procedure took 6 months. In order to confirm the successful establishment of HCC827 GR cell line, cell viability of HCC827 GR in different gefitinib concentrations was measured by MTT assay after culturing HCC827 GR in gefitinib-free condition for at least 4 days. At the same time, HCC827 cells were cultured in gefitinib-free condition concomitantly, and their sensitivity to gefitinib was not changed through the gefitinib sensitivity examination every 5 passages [19].

2.3. MET Amplification Detection. In the process of HCC827 GR cell line established, MET levels from parental HCC827 cell to HCC827 GR cell (the gefitinib concentration was increased gradually from 0 μM to 1 μM) were detected. MET levels of HCC827 GR cell with different treatment were detected too. Cells were collected and washed with PBS for 2 times. DNA was abstracted and purified with QIAamp DNA Mini Kit. MET amplifications were analyzed with ddPCR copy number variation (CNV) assay. QX200 ddPCR system was used to perform ddPCR. All procedures were performed according to instructions.

We followed the methods of Jin et al. 2019 [13] for the method of cell culture, medication treatment of YC-1, western blot assay, MTT assay, colony formation assay, cell migration assay, and statistical analyses. Concrete contents were described in supplementary material (available here)

3. Result

3.1. HCC827 GR Cell Line Was Established. The parental cell HCC827 was continuously exposed to gefitinib beginning at 0.001 μM and increased in a stepwise manner to 1 μM. Finally, the HCC827 GR cell line was established as shown in Figure 1(a). Gefitinib had less effect on HCC827 GR cells than that on HCC827 cells. The IC50 of gefitinib on HCC827 GR cells and HCC827 cells was 26.53 ± 0.96 μM and 0.08 ± 0.02 μM. Moreover, the morphology of HCC827 GR cells were more elongated than their parental HCC827 cells (Figure 1(b)).

3.2. YC-1 Enhances the Sensitivity of HCC827 GR Cells to Gefitinib. The concentration of YC-1 on HCC827 GR cells was determined through an MTT assay. The concentration of 40 μM was finally chosen for this experiment, for a higher concentration of YC-1 was not able to further inhibit the viability of HCC827 GR cells (Figure 2(a)). Increase of the YC-1 exposure time resulted in a decrease of the cell viability, and the effect of 40 μM YC-1 on HCC827 GR cells started at the time of 12 h and reached its optimum at the time of 24-28 h (Figure 2(b)). In order to avoid a false negative result caused by large groups of cell death while YC-1 and gefitinib combined, two time points of 16 h and 28 h were set for this study. Colony formation analysis, MTT assay, and wound healing assay were utilized to evaluate the sensitivity of HCC827 GR cells to gefitinib. In MTT assay, compared with gefitinib alone treated HCC827 GR cells, a reduction in cell viability was shown when HCC827 GR cells were treated with YC-1 and gefitinib combined for both 16 h and 28 h (P < 0.01; Figure 3), though this phenomenon was also presented in HCC827 cells (P < 0.05; Figure 3). In the colony formation analysis, YC-1 alone for both 16 h and 28 h can inhibit the colony formation ability of HCC827 GR cells (P < 0.05; Figure 4). Gefitinib and YC-1 together can also inhibit the colony formation ability of HCC827 GR cells (P < 0.01; Figure 4). In the wound healing assay, compared with gefitinib treatment alone, gefitinib and YC-1 combined treatment was able to inhibit cell migration (P < 0.01; Figure 5). YC-1 treatment alone for both 16 h and 28 h can also inhibit cell migration ability (P < 0.05; Figure 5).

3.3. Sensitivity of HCC827 Cells and HCC827 GR Cells to Gefitinib before and after Treatment with YC-1. HCC827 cells and HCC827 GR cells were treated with gefitinib at different concentrations (0.001, 0.01, 0.1, 1, 10, and 100 μM) and 40 μM YC-1 combined with gefitinib at different
concentrations. Cell viability was measured by MTT. Compared with gefitinib alone-treated HCC827 cells, a reduction in cell viability was observed when HCC827 cells were treated with 40 μM YC-1 and gefitinib at concentrations of 0.01, 0.1, and 1 μM (P = 0.0348, P = 0.0085, and P = 0.01726, respectively). Compared with gefitinib alone-treated HCC827 GR cells, cell viability was reduced when HCC827 GR cells were treated with 40 μM YC-1 and gefitinib at concentrations of 0, 0.001, 0.01, 0.1, 1, and 10 μM (P = 0.0089, P = 0.0075, P = 0.00116, P < 0.001, P < 0.001, and P < 0.001, respectively).

**Figure 4: Colony formation analysis in HCC827 GR cells with different treatments.** HCC827 GR cells were seeded and cultured on dishes with different treatments (blank control, YC-1, gefitinib, YC-1, and gefitinib combined, for 16 h and 28 h), then, cells were culture for 2 weeks in media without drugs. (a) Colony formation of HCC827 GR cells observed by naked eyes. (b) Colony formation of HCC827 GR cells observed under microscope (magnification, ×40). (c) Quantified results of colony formation analysis. The concentration of YC-1 was 40 μM, and the final concentration of gefitinib was 20 nM. Error bars represented the mean ± SD. Data were obtained from three independent experiments. *P < 0.05 and **P < 0.01.
At the gefitinib concentration of 0.1 μM, the sensitivity to gefitinib of HCC827 GR cells treated with 40 μM YC-1 was enhanced compared with that of HCC827 cells treated with 40 μM YC-1 (P = 0.0062). At other gefitinib concentrations, there was no significant difference at the sensitivity to gefitinib between HCC827 cells and HCC827 GR cells treated with 40 μM YC-1 (Figure 6). These indicated that 40 μM YC-1 was able to reverse the resistance of HCC827 GR cells to gefitinib and even presented enhanced sensitivity of HCC827 GR cells to gefitinib at treatment concentration compared with the parental cells.

3.4. The Detection of MET Amplification in HCC827 GR Cells and the Influence of HIF-1 Pathway Downregulation to MET Amplification. After the HCC827 GR cell line was established, MET amplification was detected. The MET level of HCC827 GR cells reached to more than 5 times of its parental cell. In the process of the HCC827 GR cell line established in
**4. Discussion**

In the present study, the inhibition of the HIF-1 pathway by YC-1 can make the HCC827 GR cell more sensitive to gefitinib. Through the comparison of gefitinib sensitivity among HCC827 cells, HCC827 GR cells, HCC827 cells treated with YC-1, and HCC827 GR cells treated with YC-1, it finally revealed that HIF-1 inhibitor YC-1 reversed the acquired resistance of HCC827 GR cells to gefitinib. In our previous research, we also found that the HIF-1 inhibitor was able to enhance the sensitivity of HCC827 cells to gefitinib [13].

Hypoxic tumor cells activate a series of signal pathways to adapt to the hypoxic condition. In these signal pathways, the HIF-1 signal pathway is the most well-defined and important pathway. HIF-1 pathway has more than 100 target genes which allow the tumor cells to survive and proliferate under hypoxic condition [20, 21]. HIF-1 keeps a stable construction in hypoxia. Then, it transfers to the nucleus and activates the expression of its target genes [8]. These activated genes prevent apoptosis and promote therapy resistance by regulating cell metabolism, survival, drug efflux, signaling, and DNA repair [22–26]. Thus, inhibiting the HIF-1 pathway is able to enhance the sensitivity of anticancer therapy theoretically.

For the HIF-1 pathway in EGFR-TKI therapy resistance, previous research showed the upregulation of HIF-1α [12]. Furthermore, the quantity of NSCLC stem cells which were resistant to EGFR-TKIs in EGFR mutant NSCLC was increased under hypoxic condition [11]. In acquired EGFR-TKI-resistant NSCLC cells with MET amplification, EGFR lost its regulation on MET, and whether the HIF-1 pathway remained the regulation on MET kept unclear [7]. Meanwhile, HCC827 GR is generated by exposing HCC827 cells to increasing concentrations of gefitinib, and MET amplification is the mechanism of its acquired resistance [16, 17].
our study, MET amplification of HCC827 GR was presented by ddPCR CNV assay, and the correlations between HIF-1α, p-EGFR, and p-Met levels were analyzed by Pearson’s correlation analysis. Our study showed that the p-Met level was correlated with the HIF-1α level, but there was no correlation between p-Met level and p-EGFR level. So, we speculated that the HIF-1 pathway keeps its regulation on MET while EGFR loses its regulation on MET in HCC827 GR cells with MET amplification. Accordingly, the regulation of the HIF-1 pathway on MET may be one of the mechanisms of YC-1 reversing the acquired resistance of HCC827 GR to gefitinib. Therefore, the HIF-1 pathway may be a significant target for reversing the acquired resistance of NSCLC with MET amplification to EGFR-TKIs.

5. Conclusions

HIF-1 inhibitor YC-1 is able to reverse the acquired resistance of HCC827 GR to gefitinib, and the regulation of HIF-1 pathway on MET may be one of the mechanisms.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no competing interests.

Acknowledgments

The authors would like to thank Miss Guizhi Zhao, Professor Jianying Zhou, and the respiratory research laboratory staff of First Affiliated Hospital of Zhejiang University School of Medicine for providing technical assistance. This study was funded by Medicine and Health Projects of Zhejiang Province [2016KYB053] and Chinese Medicine Scientific Projects of Zhejiang Province [2018ZA020].

Supplementary Materials

The supplementary material described methods of cell culture, medication treatment, western blot assay, MTT assay, colony formation assay, cell migration assay and statistical analyses. (Supplementary Materials)

References

[1] V. Sosa Iglesias, L. Giuranno, L. J. Dubois, J. Theys, and M. Vooijs, "Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting?" Frontiers in oncology, vol. 8, p. 267, 2018.

[2] A. C. Z. Gelatti, A. Drilon, and F. C. Santini, "Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)," Lung Cancer, vol. 137, pp. 113–122, 2019.

[3] J. Franek, J. C. Cappelleri, K. A. Larkin-Kaiser, K. D. Wilner, and R. Sandin, "Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer," Front Oncol, vol. 15, no. 24, pp. 2857–2871, 2019.

[4] W. H. Hsu, J. C. Yang, T. S. Mok, and H. H. Loong, "Overview of current systemic management of EGFR-mutant NSCLC," Annals of Oncology, vol. 29, supplement_1, pp. i3–i9, 2018.

[5] S. M. Lim, N. L. Syn, B. C. Cho, and R. A. Soo, "Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies," Cancer Treatment Reviews, vol. 65, pp. 1–10, 2018.

[6] D. Westover, J. Zugazagoitia, B. C. Cho, C. M. Lovly, and L. Paz-Ares, "Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors," Annals of Oncology, vol. 29, supplement_1, pp. i10–i19, 2018.

[7] J. A. Engelman, K. Zejnulaahlu, T. Mitsudomi et al., "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling," Science, vol. 316, no. 5827, pp. 1039–1043, 2007.

[8] S. K. Burroughs, S. Kaluz, D. Wang, K. Wang, E. G. Van Meir, and B. Wang, "Hypoxia inducible factor pathway inhibitors as anticancer therapeutics," Future Medicinal Chemistry, vol. 5, no. 5, pp. 553–572, 2013.

[9] W. Wilson and M. Hay, "Targeting hypoxia in cancer therapy," Nature Reviews. Cancer, vol. 11, no. 6, pp. 393–410, 2011.

[10] G. L. Wang, B. H. Jiang, E. A. Rue, and G. L. Semenza, "Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension," Proc Natl Acad Sci USA, vol. 92, no. 12, pp. 5510–5514, 1995.

[11] A. Murakami, F. Takahashi, F. Nurwidya et al., "Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor," PLoS One, vol. 9, article 86459, 2014.

[12] F. Morgillo, "Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors," British Journal of Cancer, vol. 105, no. 3, pp. 382–392, 2011.

[13] Q. Jin, J. Zhou, X. Xu, F. Huang, and W. Xu, "Hypoxia-inducible factor-1 signaling pathway influences the sensitivity of HCC827 cells to gefitinib," Oncology Letters, vol. 17, no. 4, pp. 4034–4043, 2019.

[14] F. N. Ko, C. C. Wu, S. C. Kuo, F. Y. Lee, and C. M. Teng, "YC-1, a novel activator of platelet glycanyl cyclase," Blood, vol. 84, no. 12, pp. 4226–4233, 1994.

[15] Y. S. Chun, E. J. Yeo, E. Choi et al., "Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells," Biochemical Pharmacology, vol. 61, no. 8, pp. 947–954, 2001.

[16] W. J. Jang, S. K. Jung, J. S. Kang et al., "Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification," Cancer Science, vol. 105, no. 10, pp. 1245–1253, 2014.

[17] J. K. Rho, Y. J. Choi, S. Y. Kim et al., "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation," Cancer Research, vol. 74, no. 1, pp. 253–262, 2014.

[18] L. Xu, M. B. Nilsson, P. Saintigny et al., "Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells," Oncogene, vol. 29, no. 18, pp. 2616–2627, 2010.

[19] J. A. Engelman, T. Mukohara, K. Zejnulaahlu et al., "Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer," The Journal of Clinical Investigation, vol. 116, no. 10, pp. 2695–2706, 2006, Epub 2006 Aug 10.

[20] C. Wigerup, S. Pahlman, and D. Bexell, "Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer," Pharmacology & Therapeutics, vol. 164, pp. 152–169, 2016.

[21] N. A. Warfel and W. S. El-Deiry, "HIF-1 signaling in drug resistance to chemotherapy," Current Medicinal Chemistry, vol. 21, no. 26, pp. 3021–3028, 2014.

[22] K. M. Comerford, T. J. Wallace, J. Karhausen, N. A. Louis, M. C. Montalto, and S. P. Colgan, "Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene," Cancer Research, vol. 62, no. 12, pp. 3387–3394, 2002.

[23] M. C. Brahim-Horn, G. Bellot, and J. Pouysségur, "Hypoxia and energetic tumour metabolism," Current Opinion in Genetics & Development, vol. 21, no. 1, pp. 67–72, 2011.

[24] L. Liu, X. Ning, L. Sun et al., "Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer," Cancer Science, vol. 99, no. 1, pp. 121–128, 2008.
[25] D. Wu, B. Chen, F. Cui, X. He, W. Wang, and M. Wang, "Hypoxia-induced microRNA-301b regulates apoptosis by targeting Bim in lung cancer," Cell Proliferation, vol. 49, no. 4, pp. 476–483, 2016.

[26] F. Liu, L. Hu, Y. Ma et al., "Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer," Oncology Letters, vol. 15, no. 3, pp. 3245–3251, 2018.